Who are Rucacuzumab plus standard therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Veopoz, AVACINCAPTAD PEGOL SODIUM, Ultomiris, H5G1.1, BKEMV, Eculizumab+IVMP.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rucacuzumab-plus-standard-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Rucacuzumab plus standard therapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rucacuzumab plus standard therapy (Rucacuzumab plus standard therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody; complement inhibitor. Area: Immunology; Rheumatology.

marketed Monoclonal antibody; complement inhibitor C1q (complement component 1q) Immunology; Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

Rucacuzumab plus standard therapy (Rucacuzumab plus standard therapy) — Peking Union Medical College Hospital. Rucacuzumab is a monoclonal antibody that binds to complement component C1q to inhibit the classical complement pathway, reducing inflammatory and immune-mediated tissue damage.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rucacuzumab plus standard therapy TARGET	Rucacuzumab plus standard therapy	Peking Union Medical College Hospital	marketed	Monoclonal antibody; complement inhibitor	C1q (complement component 1q)
Veopoz	POZELIMAB	Regeneron	marketed	Complement Inhibitor [EPC]	Complement C5	2023-01-01
AVACINCAPTAD PEGOL SODIUM	AVACINCAPTAD PEGOL SODIUM		marketed	Complement Inhibitors	Complement C5	2023-01-01
Ultomiris	RAVULIZUMAB	AstraZeneca	marketed	Complement Inhibitor [EPC]	Complement C5	2018-01-01
H5G1.1	ECULIZUMAB	AstraZeneca	marketed	Complement Inhibitor [EPC]	C5	2007-01-01
BKEMV	ECULIZUMAB-AEEB	AMGEN INC	marketed	Complement Inhibitor [EPC]
Eculizumab+IVMP	Eculizumab+IVMP	Chinese PLA General Hospital	marketed	Complement inhibitor + corticosteroid combination	Complement C5 + glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-11-11 — AVACINCAPTAD PEGOL SODIUM · 8236773 · Method of Use · US
2027-02-14 — AVACINCAPTAD PEGOL SODIUM · 9617546 · Compound · US
2027-02-14 — AVACINCAPTAD PEGOL SODIUM · 7579456 · Compound · US
2034-07-11 — AVACINCAPTAD PEGOL SODIUM · 11491176 · Method of Use · US
2034-07-11 — AVACINCAPTAD PEGOL SODIUM · 11273171 · Method of Use · US
2034-07-11 — AVACINCAPTAD PEGOL SODIUM · 12016875 · Method of Use · US

Sponsor landscape (Monoclonal antibody; complement inhibitor class)

Peking Union Medical College Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rucacuzumab plus standard therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/rucacuzumab-plus-standard-therapy. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab